Navigation Links
Neuralstem Updates ALS Stem Cell Trial Progress
Date:5/8/2012

y designed as a safety trial to treat 18 patients.

"The return of these patients to the trial for second treatments is a continuing validation of the trial's safety. Typically, Phase I trials do not bring study subjects back, as that could increase their exposure to potentially harmful treatments," said Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer. "Treating these patients who have already received injections in one part of their spine allows us to both increase the overall dosage for each patient as well as transplant them in regions of the spine where they have not been treated," Dr. Johe continued. "This next cohort of patients will be the first in the world to receive stem cell transplants in both cervical and lumbar regions of their spinal cord. With cervical injections of the lumbar patients, for example, we could also potentially support their breathing function, which is vital for preserving quality of life."

"Patients 10-12, who might return to the trial, were among those studied in a paper examining the first safety data from the trial, published online in STEM CELLS last month," said Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System.  "As the paper showed, we believe that the cells and the route of administration are safe. It is a further validation of the safety profile to be able to bring patients back for additional dosing several months past the period which was reported on in the journal." Dr. Feldman is also principal investigator (PI) of the ALS trial and an unpaid Neuralstem consultant.

The FDA-approved amendment to the protocol requires approval of the Emory Institutional Review Board before it can be implemented.

About the Study

The ongoing Phase I study is designed to assess the safety of Neuralstem's spinal cord stem cells (HSSC's) and transplantation
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... enrollment and dosing of patients in its ongoing Phase ... pancreatic cancer under the revised clinical protocol agreed to ... PEGylated form of Halozyme,s proprietary recombinant human hyaluronidase under ... hyaluronan. "Our diligent effort to rapidly ...
(Date:7/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... chief financial officer of the company, effective July 22, ... president and chief financial officer of Elan Corporation, a ... was part of a senior team that helped build ... to Perrigo, a pharmaceutical manufacturer, in December 2013. ...
(Date:7/22/2014)... 22, 2014  UL (Underwriters Laboratories), a global ... Food and Drug Administration (FDA) has recognized two ... medical devices incorporating lithium or nickel-based batteries. The ... Household and Commercial Batteries, and UL 1642 - ... Consensus standards are standards recognized by the FDA ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3ConvaTec Names Nigel Clerkin Chief Financial Officer 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... Women ages 65-69 who break a hip are five times more ... age who don,t break a hip, according to a Kaiser Permanente ... Health and published online today in the Archives of Internal ... by age group. In addition to the finding for women ages ...
... 26, 2011 UHC, an alliance of the nation,s ... a mobile analytics application for Spend LINK®, UHC,s ... subset of Spend LINK® reports that can be ... developed by Novation, UHC,s supply contracting company, allows users ...
Cached Medicine Technology:Elderly Women Who Break a Hip at Increased Risk of Dying Within a Year 2Elderly Women Who Break a Hip at Increased Risk of Dying Within a Year 3Elderly Women Who Break a Hip at Increased Risk of Dying Within a Year 4UHC Launches Analytics Mobile App to Help Members Improve Supply Chain Return on Investment 2UHC Launches Analytics Mobile App to Help Members Improve Supply Chain Return on Investment 3
(Date:7/22/2014)... Greensboro, NC (PRWEB) July 22, 2014 ... and faster for military veterans who have hands-on medical ... North Carolina at Greensboro today announced the launch of ... for military experience. , The new program, the UNCG ... a cohort of approximately 24 veterans. With some prior ...
(Date:7/22/2014)... Rosa Beach, FL (PRWEB) July 22, 2014 ... announce that they are now an authorized Daikin comfort ... offer and install Daikin indoor heating and cooling system ... and each one is thoroughly reviewed before being approved. ... is an innovator in the Split System Air Conditioning ...
(Date:7/22/2014)... Dr. Jeremy K. Ueno, of ... recently discussed the reasons for an increase in patients ... profession are seeing the amount of referrals they get ... one surgeon reported that over 50% of his implant ... have a very high success rate of up to ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's ... McPhearson, an insurance veteran with more than 15 years ... be based in the company's Chicago office. , UBA ... Les chose to accept this important, strategic position with ... many challenges facing UBA and its Partners as we ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 A Florida ... ) that alleges the death of her husband ... the blood thinner, Bernstein Liebhard LLP reports. According to ... District Court for the Southern District of Florida on ... 2012, and suffered a subdural hemorrhage the following June. ...
Breaking Medicine News(10 mins):Health News:UNCG School of Nursing Fast-Tracks Medically Trained Veterans 2Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 2Health News:Dr. Jeremy Ueno Can Help Treat Patients That Have Failing Implants 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3
... at Intermountain Medical Center in Salt Lake City believe ... fibrillation, a fairly common heart rhythm disorder, and Alzheimer,s ... In a study presented Friday, May 15, at "Heart ... Rhythm Society in Boston, researchers unveiled findings from the ...
... HAIKOU CITY, China, May 15 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ... specialty pharmaceutical products in China, today,announced financial results for the ... First Quarter 2009 Financial Highlights, -- ... the, first quarter of ...
... Prayerful Approach to Pain in Steinbach, Manitoba , ... Steinbach, Manitoba, Canada ... suffer in silence from chronic pain. Even pop singer, famed choreographer, and ... chronic pain in the May issue of Ladies Home Journal. While ...
... Brookdale Senior Living Inc. (NYSE: BKD ) today ... will make a presentation regarding the Company at the JMP ... 19, 2009, beginning at 2:30 p.m. Pacific Time.The presentation is ... Internet at , http://www.wsw.com/webcast/jmp8/bkd/ ...
... 14, 2009)A study of targeted educational initiatives between the ... hospitals within their Partners program suggest that educational interventions ... for cancer patients at community hospitals. The study, ... the American Society of Clinical Oncology, looked specifically at ...
... cancer patients , , THURSDAY, May 14 (HealthDay News) -- ... many grandmothers are already familiar with, and report that ... , "Ginger at a daily dose of 0.5-to-1 gram ... the first day of chemotherapy, and reduced nausea will ...
Cached Medicine News:Health News:Study makes first connection between heart disorder and Alzheimer's disease 2Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 2Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 3Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 4Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 5Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 6Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 7Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 8Health News:Chronic Pain Sufferers Find Hope in the Darkness 2Health News:Educational initiatives improve quality of care delivery 2Health News:Ginger Eases Nausea From Chemo 2
... Arctic Circler uses the same cryoconsole ... AF originating in the pulmonary veins. Arctic ... challenge the traditional palliative-only treatments that rely ... the Arctic Circler catheter has the ability ...
... The Guglielmi Detachable Coil is intended for: ... because of,their morphology, their location, or the ... by the treating,neurosurgical team to be a) ... operative techniques, or b) inoperable.,The GDC is ...
Care must be taken to operate the power unit slowly to help eliminate the possibility of breaking the wires by over-tightening....
Large solid mallet with patented Ortho-Grip® silicone rubber handle....
Medicine Products: